Skip to Main Content

Paper Details

Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.
Cancer Res
2
2023
-, C, CDK4/6, ESR1, ESR1 Fusion-Driven Breast Cancer, ESR1 fusions, ET, ET-resistant, ET-resistant patient-derived xenograft model, RET, RET kinase, TAF, TAFs, YAP1, breast cancer, breast tumors, e6, estrogen, palbociclib, pan-, patient, pralsetinib, translocated in-frame partner gene sequences
Author NameAffiliation
Xuxu GouBaylor College of Medicine
Xuxu GouUCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco
Xuxu GouBaylor College of Medicine
Beom-Jun KimBaylor College of Medicine
Beom-Jun KimBaylor College of Medicine
Beom-Jun KimBaylor College of Medicine
Beom-Jun KimBaylor College of Medicine
Meenakshi AnuragBaylor College of Medicine
Meenakshi AnuragBaylor College of Medicine
Jonathan T LeiBaylor College of Medicine
Jonathan T LeiBaylor College of Medicine
Purba SinghBaylor College of Medicine
Anna MalovannayaBaylor College of Medicine
Lacey E DobroleckiBaylor College of Medicine
Michael T LewisBaylor College of Medicine
Michael T LewisBaylor College of Medicine
Michael T LewisDan L. Duncan Cancer Center, Baylor College of Medicine
Michael T LewisBaylor College of Medicine
Michael T LewisBaylor College of Medicine
Michael T LewisBaylor College of Medicine
Michael T LewisDan L. Duncan Cancer Center, Baylor College of Medicine
Michael T LewisBaylor College of Medicine
Shunqiang LiWashington University School of Medicine
Charles E FouldsBaylor College of Medicine
Charles E FouldsBaylor College of Medicine
Charles E FouldsDan L. Duncan Cancer Center, Baylor College of Medicine
Matthew J EllisBaylor College of Medicine
Matthew J EllisBaylor College of Medicine
Matthew J EllisBaylor College of Medicine
Matthew J EllisBaylor College of Medicine
Matthew J EllisDan L. Duncan Cancer Center, Baylor College of Medicine
  • 1 - 31

Datasets

Release 1.2